58 studies found for:    pasireotide
Show Display Options
Rank Status Study
1 Completed Trial to Assess the Mechanism(s) Responsible for the Effect of the Somatostatin Analogue SOM230 (Pasireotide) in Healthy Male Volunteers
Condition: Hyperglycemia
Intervention: Drug: pasireotide
2 Recruiting Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.
Conditions: Cushing's Disease,;   Acromegaly,;   Neuroendocrine Tumors,;   Pituitary Tumors;   Ectopic ACTH Secreting (EAS) Tumors,;   Dumping Syndrome,;   Prostate Cancer,;   Melanoma Negative for bRAF,;   Melanoma Negative for nRAS
Intervention: Drug: Pasireotide
3 Recruiting Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)
Condition: Neuroendocrine Tumors
Intervention: Drug: Pasireotide LAR
4 Unknown  Pasireotide LAR Administration in Lymphocele Prevention After Axillary Node Dissection for Breast Cancer
Condition: Breast Cancer
Interventions: Drug: PASIREOTIDE;   Drug: PLACEBO
5 Completed Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function
Conditions: Hepatic Cirrhosis;   Alcoholism
Intervention: Drug: Pasireotide
6 Recruiting Pasireotide LAR in Severe Polycystic Liver Disease
Conditions: Somatostatin Analogs;   Polycystic Liver Disease;   Autosomal Dominant Polycystic Kidney Disease;   Autosomal Dominant Polycystic Liver Disease
Interventions: Drug: Pasireotide LAR;   Drug: Placebo
7 Recruiting RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma
Condition: Uveal Melanoma
Intervention: Drug: RAD001 (Everolimus) and Pasireotide (SOM230) LAR
8 Active, not recruiting Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Condition: Advanced Adult Hepatocellular Carcinoma
Interventions: Drug: Everolimus;   Drug: Pasireotide
9 Recruiting A Trial of Pasireotide and Everolimus in Adult Patients With Radioiodine-Refractory Differentiated and Medullary Thyroid Cancer
Condition: Thyroid Cancer
Interventions: Drug: Everolimus;   Drug: Pasireotide;   Drug: Everolimus and Pasireotide
10 Active, not recruiting Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess
Condition: Pancreatic Cancer
Interventions: Drug: Pasireotide (SOM230);   Other: placebo
11 Recruiting Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Intervention: Biological: SOM230
12 Recruiting Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
Conditions: Castrate Resistant Prostate Cancer;   Chemotherapy Naive Prostate Cancer;   Prostate Cancer
Interventions: Drug: Pasireotide;   Drug: Everolimus;   Other: Laboratory biomarker analysis
13 Active, not recruiting Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
Conditions: Neuroendocrine Tumor;   Carcinoid Tumor;   Pancreatic Neuroendocrine Tumor
Interventions: Drug: SOM230;   Drug: RAD001
14 Recruiting Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: docetaxel;   Drug: pasireotide;   Drug: prednisone
15 Completed
Has Results
Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease
Condition: Symptomatic Refractory Resistant Carcinoid Disease
Interventions: Drug: Pasireotide;   Drug: Octreotide
16 Active, not recruiting Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs
Condition: Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System
Interventions: Drug: Pasireotide LAR followed by Pasireotide LAR + Everolimus;   Drug: Everolimus followed by Pasireotide LAR + Everolimus
17 Recruiting Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
Condition: Cushing's Disease
Interventions: Drug: SOM230 LAR 30 mg;   Drug: SOM230 LAR 10 mg
18 Recruiting Pasireotide Therapy in Patients With Nelson's Syndrome
Condition: Nelson Syndrome
Intervention: Drug: Pasireotide
19 Terminated Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas
Condition: Gonadotroph Adenomas
Intervention: Drug: pasireotide LAR
20 Recruiting 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial
Condition: Neuroendocrine Carcinoma of the Lung and Thymus
Interventions: Drug: Pasireotide LAR;   Drug: Everolimus;   Drug: Pasireotide LAR + Everolimus

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years